Conditioned medium from amniotic fluid mesenchymal stem cells could modulate Alzheimer's disease-like changes in human neuroblastoma cell line SY-SY5Y in a paracrine manner. (June 2022)

• Record Type: Journal Article
• Authors: Hasanpour, Milad; Rahbarghazi, Reza; Nourazarian, Alireza; Khaki-Khatibi, Fatemeh; Avci, Çigir Biray; Hassanpour, Mehdi; Talebi, Mehdi; Taghavi, Hossein; Salimi, Leila
• Is Part Of: Tissue & cell. Volume 76(2022)
• Publication Date: 2022-06
• Subjects: Aβ Amyloid-beta -- ACE Angiotensin-converting enzyme -- AD Alzheimer's disease -- ADMSCs Adipose-derived mesenchymal stem cells -- APP Amyloid precursor protein -- BSA Bovine serum albumin -- CDK5 Cyclin-dependent kinase 5 -- CM Conditioned medium -- DC Dendritic cells -- DMEM Dulbecco's Modified Eagle's Medium -- DMSO Dimethyl sulfoxide -- ELISA Enzyme-linked Immunosorbent Assay -- FBS Fetal Bovine Serum -- GSK3β Glycogen synthase kinase 3 Beta -- HLA Human Leukocyte Antigen -- IBD Inflammatory bowel disease -- LPS Lipopolysaccharides -- MMP-9 Matrix metalloproteinases -- MSCs Mesenchymal stem cell -- NEP Neprilysin -- NFT Neurofibrillary tangles -- NGFs Nerve growth factors -- PBS Phosphate Buffer Saline; Alzheimer's disease -- Amniotic fluid mesenchymal stem cells -- Beta-amyloid -- Neurogenesis; Cytology -- Periodicals; 571.5
• DOI: 10.1016/j.tice.2022.101808
• Languages: English
• ISSNs: 0040-8166

Abstract

Abstract: Background: Alzheimer's disease is usually diagnosed by significant extracellular deposition of beta-amyloid and intracellular neurofibrillary tangle formation. Here, we investigated the paracrine effect of amniotic fluid-derived mesenchymal stem cells on AD changes in human SH–SY5Y cells. Methods: SH–SY5Y cells were divided into five groups: Control, 0.1 µg/ml LPS, 10 µg/ml LPS, 0.1 µg/ml LPS + conditioned medium, and 10 µg/ml LPS + conditioned medium. Cells were incubated with 0.1% and 10 µg/ml LPS for 48 h, followed by incubation with the conditioned medium of amniotic fluid-derived mesenchymal stem cells for the next 24 h. Beta-amyloid plaques were monitored by Congo-red staining. Survival and apoptosis were assessed by the MTT assay and flow cytometric analysis of Annexin-V. ELISA was used to measure the levels of neprilysin, angiotensin-converting enzyme, and Matrix Metalloproteinase–9. A PCR array was used to measure the expression of genes involved in neurogenesis. Results: Bright-field imaging showed beta-amyloid plaques in the group treated with 10 µg/ml LPS. We found minimal effects in groups receiving 0.1 µg/ml LPS. The data showed that the reduction in the levels of neprilysin, angiotensin-converting enzyme, and Matrix Metalloproteinase–9 in the LPS-treated cells was attenuated after incubation with the stem cell secretome (p < 0.05). Amniotic fluid stem cell secretome increased the viability of LPS-treated SH–SY5Y cells (p 0.05) and was associated with a decrease in apoptotic changes (p < 0.05). We found the modulation of several genes involved in neurogenesis in the 10 µg/ml LPS + conditioned medium group compared to cells treated with 10 µg/ml LPS alone. Conclusion: Amniotic fluid stem cell secretion reduces AD-like pathologies in the human neuronal lineage. Highlights: Amniotic fluid stem cell secretome increased the viability of LPS-treated SH-SY5Y cells. AF-MSCs-CM exerts a protective effect on SHSY5Y cells exposed to bacterial LPS. AF-MSCs-CM could increase cell viability and Aβ- degrading enzymes leading to the reduction of AD-like pathologies.